ReviewWorld journal of gastroenterology2026
Misdiagnosis of alpha-gal syndrome as non-celiac gluten sensitivity or lactose intolerance: A diagnostic blind spot for clinicians.
Review in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-gal syndrome (AGS), an emerging tick-borne carbohydrate hypersensitivity, has gained increasing recognition for its atypical presentation and delayed food-related allergic reactions. While urticaria and anaphylaxis dominate the clinical narrative, gastrointestinal (GI) manifestations-including abdominal pain, diarrhea, bloating, and cramping-are common and often underrecognized. These nonspecific GI symptoms create significant diagnostic overlap with prevalent functional and food-related disorders such as non-celiac gluten sensitivity (NCGS) and lactose intolerance. Consequently, many patients with AGS undergo unnecessary dietary restrictions, prolonged symptom burden, or misdirected therapies before an accurate diagnosis is established. The knowledge gap lies in the limited awareness of AGS as a differential diagnosis for food-related GI complaints, especially in regions endemic to tick exposure. Unlike gluten or lactose intolerance, AGS reactions are characterized by a unique delayed onset (2-6 hours postprandially) and a distinct immunologic mechanism mediated by IgE to galactose-α-1,3-galactose. However, clinicians rarely consider AGS when evaluating chronic, unexplained food-triggered symptoms, perpetuating diagnostic blind spots. Current guidelines for evaluating NCGS and lactose intolerance seldom incorporate testing for alpha-gal IgE, despite growing evidence that a subset of misdiagnosed patients may in fact harbor AGS. Clinically, this misclassification carries significant consequences: Patients may continue mammalian food exposure with risk of escalating allergic reactions, including life-threatening anaphylaxis, while adhering to unnecessary or ineffective gluten-free or lactose-free diets. Raising awareness, integrating alpha-gal IgE testing into gastroenterology workups, and refining diagnostic algorithms are urgently needed. Addressing this blind spot has the potential to reduce morbidity, improve diagnostic accuracy, and optimize individualized patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.